Exact Mass: 377.211459
Exact Mass Matches: 377.211459
Found 53 metabolites which its exact mass value is equals to given mass value 377.211459,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
5-Fluoro-adb, (+/-)-
N-((1-(5-Fluoropentyl)-1H-indazol-3-yl)carbonyl)-3-methyl-D-valine methyl ester
Quilostigmine
1,3a,8-Trimethyl-1H,2H,3H,3ah,8H,8ah-pyrrolo[2,3-b]indol-5-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid
4-(1-phenylethyl)-n-[4-(1-phenylethyl)phenyl]aniline
4-(1-phenylethyl)-n-[4-(1-phenylethyl)phenyl]aniline
(7E,9aS,11S,13S,13aS)-2,3,4,5,6,8,9,9a,10,11,12,13-dodecahydro-4,11-dimethyl-8-oxo-1H-indeno[1,7a-c]azonine-11,13-diyl diacetate|N-methyllycoposerramine-T
(7E,9aS,11S,13S,13aS)-2,3,4,5,6,8,9,9a,10,11,12,13-dodecahydro-4,11-dimethyl-8-oxo-1H-indeno[1,7a-c]azonine-11,13-diyl diacetate|N-methyllycoposerramine-T
20-ethyl-1alpha,6beta,8-trihydroxy-4-methyl-heteratisan-14-one|Hetereophyllidin|O1-demethyl-heteratisine
20-ethyl-1alpha,6beta,8-trihydroxy-4-methyl-heteratisan-14-one|Hetereophyllidin|O1-demethyl-heteratisine
GR 46611
3-[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]-N-(4-methoxybenzyl)acrylamide
GR-46611 is a 5-HT1D receptor agonist. GR-46611 can be used in the research of bladder hyperactivity, leukemia[1][3].
1-O-tert-butyl 4-O-ethyl 4-[(4-methoxyphenyl)methyl]piperidine-1,4-dicarboxylate
1-O-tert-butyl 4-O-ethyl 4-[(4-methoxyphenyl)methyl]piperidine-1,4-dicarboxylate
POLY(4-VINYLPYRIDINIUM POLY(HYDROGEN
POLY(4-VINYLPYRIDINIUM POLY(HYDROGEN
C21H26F3N3 (377.20787120000006)
(3R,4S)-tert-Butyl 2-oxo-4-phenyl-3-(triethylsilyloxy)azetidine-1-carboxylate
(3R,4S)-tert-Butyl 2-oxo-4-phenyl-3-(triethylsilyloxy)azetidine-1-carboxylate
Morazone
Morazone
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
1-(6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[D]azepin-7-YL)oxy)pyridin-3-YL)pyrrolidin-2-one
1-(6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[D]azepin-7-YL)oxy)pyridin-3-YL)pyrrolidin-2-one
Carmegliptin
Carmegliptin
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
7-[(4-Methyl-1-piperazinyl)methyl]-5-(phenylmethoxymethyl)-8-quinolinol
7-[(4-Methyl-1-piperazinyl)methyl]-5-(phenylmethoxymethyl)-8-quinolinol
12-(Phosphonooxy)octadecanoate(3-)
12-(Phosphonooxy)octadecanoate(3-)
C18H34O6P-3 (377.20928940000005)
N-[[(2S,3R,4R)-3-[4-(1-cyclopentenyl)phenyl]-4-(hydroxymethyl)-2-azetidinyl]methyl]-N-methyl-2-pyridinecarboxamide
N-[[(2S,3R,4R)-3-[4-(1-cyclopentenyl)phenyl]-4-(hydroxymethyl)-2-azetidinyl]methyl]-N-methyl-2-pyridinecarboxamide
1-[(3aR,4R,9bS)-4-(hydroxymethyl)-5-methyl-8-[(E)-prop-1-enyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-2-pyridin-3-ylethanone
1-[(3aR,4R,9bS)-4-(hydroxymethyl)-5-methyl-8-[(E)-prop-1-enyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-2-pyridin-3-ylethanone
2-cyclopropyl-1-[(2S,3R)-2-(hydroxymethyl)-3-phenyl-6-(3-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-1-yl]ethanone
2-cyclopropyl-1-[(2S,3R)-2-(hydroxymethyl)-3-phenyl-6-(3-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-1-yl]ethanone
cyclobutyl-[(2S,3R)-2-(hydroxymethyl)-3-phenyl-1-(3-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-6-yl]methanone
cyclobutyl-[(2S,3R)-2-(hydroxymethyl)-3-phenyl-1-(3-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-6-yl]methanone
cyclobutyl-[(2R,3R)-2-(hydroxymethyl)-3-phenyl-1-(3-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-6-yl]methanone
cyclobutyl-[(2R,3R)-2-(hydroxymethyl)-3-phenyl-1-(3-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-6-yl]methanone
2-cyclopropyl-1-[(2R,3R)-2-(hydroxymethyl)-3-phenyl-1-(2-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-6-yl]ethanone
2-cyclopropyl-1-[(2R,3R)-2-(hydroxymethyl)-3-phenyl-1-(2-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-6-yl]ethanone
1-[(3aR,4S,9bS)-4-(hydroxymethyl)-5-methyl-8-[(E)-prop-1-enyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-2-pyridin-3-ylethanone
1-[(3aR,4S,9bS)-4-(hydroxymethyl)-5-methyl-8-[(E)-prop-1-enyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-2-pyridin-3-ylethanone
1-[(3aS,4R,9bR)-4-(hydroxymethyl)-5-methyl-8-[(E)-prop-1-enyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-2-pyridin-3-ylethanone
1-[(3aS,4R,9bR)-4-(hydroxymethyl)-5-methyl-8-[(E)-prop-1-enyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-2-pyridin-3-ylethanone
1-[(3aS,4S,9bR)-4-(hydroxymethyl)-5-methyl-8-[(E)-prop-1-enyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-2-pyridin-3-ylethanone
1-[(3aS,4S,9bR)-4-(hydroxymethyl)-5-methyl-8-[(E)-prop-1-enyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-2-pyridin-3-ylethanone
2-cyclopropyl-1-[(2S,3R)-2-(hydroxymethyl)-3-phenyl-1-(2-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-6-yl]ethanone
2-cyclopropyl-1-[(2S,3R)-2-(hydroxymethyl)-3-phenyl-1-(2-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-6-yl]ethanone
2-cyclopropyl-1-[(2S,3S)-2-(hydroxymethyl)-3-phenyl-1-(2-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-6-yl]ethanone
2-cyclopropyl-1-[(2S,3S)-2-(hydroxymethyl)-3-phenyl-1-(2-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-6-yl]ethanone
MCU-i4
MCU-i4
MCU-i4 blocks the IP3-dependent mitochondrial Ca2+-uptake, maintaining the gatekeeping role of their target[1][2].
(2e)-n-[(1s,2s,4's,5'r,6s)-5'-hydroxy-3-oxo-7-oxaspiro[bicyclo[4.1.0]heptane-2,2'-oxolan]-4-en-4'-yl]dodec-2-enimidic acid
(2e)-n-[(1s,2s,4's,5'r,6s)-5'-hydroxy-3-oxo-7-oxaspiro[bicyclo[4.1.0]heptane-2,2'-oxolan]-4-en-4'-yl]dodec-2-enimidic acid